Rennie Orange-Flavored Chewable Tablets, No. 24 (12 x 2)

In stock: 1
$48.00

Ingredients

Active ingredients: calcium carbonate, heavy magnesium carbonate;

1 tablet contains 680 mg of calcium carbonate (272 mg of elemental calcium) and 80 mg of heavy magnesium carbonate;

Inactive ingredients: sucrose, pregelatinized corn starch, potato starch, talc, magnesium stearate, light mineral oil, sodium saccharin, orange flavoring.

Dosage Form

Chewable tablets.

Main physical and chemical properties: cream-white, square tablets with concave surfaces, engraved with “RENNIE” on both sides, with an orange scent.

Pharmacotherapeutic group

Antacids, other combinations. ATC code A02A X.

Pharmacological properties

Pharmacodynamics.

Rennie® is a combination of two antacids—calcium carbonate and magnesium carbonate—which exert a local effect by neutralizing stomach acid, independent of systemic absorption. Calcium carbonate has a long-lasting and potent neutralizing effect. This effect is enhanced by magnesium carbonate, which also has a potent neutralizing effect. The total neutralizing capacity of the drug in vitro is 16 mEq H+ (titration to an endpoint pH of 2.5).

In healthy volunteers, neutralization begins rapidly. Administration of 2 Rennie® tablets on an empty stomach resulted in an increase of more than 1 pH unit within 5 minutes and a significant increase in gastric pH above the baseline pH, which was achieved within 2 minutes.

Pharmacokinetics.

In the stomach, calcium carbonate and magnesium carbonate react with gastric juice to form water and soluble mineral salts.

CaCO₃ + 2HCl → CaCl₂ + H₂O + CO₂

 

MgCO₃ + 2HCl → MgCl₂ + H₂O + CO₂

Calcium and magnesium can be absorbed in the form of their soluble salts. The rate of absorption of calcium and magnesium from these compounds depends on the dose of the medication. The maximum absorption rate is 10% for calcium and 15–20% for magnesium. In healthy volunteers, a small amount of absorbed calcium and magnesium is excreted by the kidneys. If kidney function is impaired, plasma concentrations of calcium and magnesium may increase. In the intestine, insoluble compounds are formed from the soluble salts and are excreted in the stool.

Indications

For adults and children 15 years of age and older to relieve symptoms associated with increased gastric acidity (e.g., heartburn, gastroesophageal reflux), which lead to digestive disturbances and dyspepsia.

Contraindications

  • Hypersensitivity to any component of the drug;
  • hypercalcemia and/or conditions leading to hypercalcemia;
  • nephrolithiasis caused by the formation of calcium-containing stones;
  • severe renal insufficiency (creatinine clearance below 30 mL/min);
  • hypophosphatemia.

Interactions with Other Medications and Other Types of Interactions

It is recommended that other medications be taken 1–2 hours before or after taking Rennie®.

Antacids containing calcium and magnesium may form complexes with certain substances. Therefore, when Rennie® is used concomitantly with antibiotics (tetracyclines, quinolones), cardiac glycosides (digoxin), phosphates, fluoride compounds, iron-containing products, levothyroxine, and eltrombopag, the absorption of the latter is reduced.

Thiazide diuretics reduce urinary calcium excretion and increase serum calcium levels. Due to the increased risk of hypercalcemia when thiazide diuretics are used concomitantly, serum calcium levels should be monitored regularly.

Calcium salts reduce the absorption of fluorides and iron-containing agents; calcium and magnesium salts may also interfere with phosphate absorption.

A 2-hour interval must be observed between administration of Rennie® and the following medications: H2-antihistamines, atenolol, metoprolol, or propanolol, chloroquine, diflunisal, digoxin, bisphosphonates, fexofenadine, glucocorticoids (prednisolone and dexamethasone, with the exception of hydrocortisone in replacement therapy), indomethacin, ketoconazole, phenothiazine neuroleptics, penicillamine, thyroxine, ethambutol, isoniazid, lansoprazole, and lincosamides.

It should be noted that when used concomitantly, there is increased renal excretion of salicylates due to alkalinization of the urine.

Sodium sulfonate—a cationic ion-exchange resin: the resin’s ability to bind potassium is reduced, which leads to a risk of metabolic alkalosis in patients with renal insufficiency.

Special Considerations for Use

If symptoms do not resolve, persist partially, or worsen after 10 days of treatment, an evaluation should be conducted to determine their cause and to review the treatment regimen. The course of treatment with Rennie® should not exceed 10 days. Adverse reactions have been observed with concomitant use of thiazide diuretics (see the “Interactions with Other Medications and Other Interactions” section). Prolonged use of the drug at high doses may lead to adverse reactions such as hypercalcemia, hypermagnesemia, and milk-alkali syndrome, especially in patients with renal insufficiency. This medication should not be taken concurrently with large amounts of milk or dairy products. Long-term use of Rennie® may increase the risk of kidney stones. When taking 4 to 5 tablets per day, the course of treatment should be short, and treatment should be discontinued immediately after symptoms subside.

It is recommended to consult a doctor in the event of: weight loss, difficulty swallowing or persistent abdominal discomfort, signs of digestive disorders—whether they have appeared for the first time or have changed in nature—or kidney failure (calcium and magnesium levels must be monitored).

Calcium carbonate and magnesium carbonate should not be used in cases of hypercalciuria. This medication should be used with caution in patients with impaired renal function. If calcium carbonate and magnesium carbonate must be used in such patients, plasma levels of calcium, phosphorus, and magnesium should be monitored regularly.

Patients with hereditary disorders accompanied by fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltose insufficiency should not take this medication, as it contains 475 mg of sucrose. This should also be taken into account by patients with diabetes mellitus.

Use during pregnancy or breastfeeding.

There are no reliable data regarding teratogenicity in animals. At high doses and with prolonged use of calcium carbonate, disturbances in bone formation have been reported.

To date, no increased risk of fetal malformations has been observed following the administration of calcium carbonate and magnesium carbonate during pregnancy. However, monitoring of pregnancies in which this combination was taken is insufficient to rule out any risk. Renni® may be prescribed during pregnancy and breastfeeding if used as directed; however, long-term use of high doses should be avoided. It should also be noted that magnesium salts may cause diarrhea, and calcium in high doses taken over a prolonged period increases the risk of hypercalcemia with calcification of various organs, particularly the kidneys.

It should be noted that during pregnancy and breastfeeding, calcium carbonate and magnesium carbonate provide a significant amount of calcium in addition to the amount obtained from food. Therefore, pregnant women should limit their use of Rennie® to 1 week and, while taking the medication, avoid regular consumption of milk (1 liter contains up to 1.2 g of elemental calcium), as well as dairy products to prevent calcium excess, which can lead to the so-called milk-alkali syndrome (Burnett’s syndrome), a rare but serious condition requiring medical attention.

Effect on the ability to drive or operate machinery.

No effect.

Directions for Use and Dosage

This medication is for oral use by adults and children 15 years of age and older. The usual daily dose is 1–2 chewable tablets during episodes of pain or heartburn; in cases of severe pain, the dose may be increased for a short period to 5 tablets per day. The duration of treatment should not exceed 10 days.

Children.

Do not use in children under 15 years of age.

Overdose

Prolonged use of high doses of calcium carbonate and magnesium carbonate, especially in patients with impaired renal function, may lead to renal failure, hypermagnesemia, hypercalcemia, and alkalosis, which manifest as gastrointestinal symptoms (nausea, vomiting, constipation) and muscle weakness. In such cases, discontinue use of the medication and ensure adequate fluid intake. In severe cases of overdose (e.g., Burnett’s syndrome), consult a doctor, as additional rehydration (e.g., via infusion) may be necessary. Diarrhea may also develop in the event of an overdose.

Side Effects

Immune system disorders.

Hypersensitivity reactions, manifesting as rashes, hives, angioedema, and anaphylaxis, have been reported very rarely.

Metabolic and nutritional disorders.

In patients, especially those with impaired renal function, prolonged use of high doses may lead to hypermagnesemia (when used with magnesium-containing antacids) or hypercalcemia and alkalosis, which manifest as gastrointestinal symptoms and muscle weakness; and there is also a risk of kidney stones and the development of renal failure.

Gastrointestinal side effects. 

Nausea, vomiting, stomach discomfort, and diarrhea may occur.

Musculoskeletal and connective tissue disorders.

Muscle weakness may occur.

Side effects observed only in milk-alkali syndrome (Burnett syndrome):

  • gastrointestinal disorders (ageusia);
  • general disorders (calcinosis and asthenia);
  • nervous system disorders (headache);
  • kidney and urinary tract disorders (azotemia).

Shelf life

3 years.

Storage Conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

6 tablets in PVC and aluminum blisters, 2 or 4 blisters in a cardboard box, or 12 tablets in perforated PVC and aluminum blisters, 1 or 2 blisters per cardboard box.

Dispensing Category

Available without a prescription.